Bugworks Research secures $18M Series B1 funding from reputed Global Investor Syndicate
BWC0977, Bugwork’s candidate for a novel broad spectrum anti-bacterial agent, will be further developed with financial support by Global Investor Syndicate led by Lightrock India. The Funding will advance highly differentiated assets in both areas, antimicrobial resistance and immuno-oncology.
The clinical stage multi-indication therapeutics company Bugworks Research shortly announced the financing of a US $18M Series B1 to support the clinical development of BWC0977, a novel broad spectrum anti-bacterial agent, available in both IV and Oral forms, and the pre-clinical development of its best-in-class Adenosine immuno-oncology asset.
Bugworks will continue to invest in its proprietary drug discovery platforms GYROX (for antimicrobial resistance) and DARE (for immuno-oncology), and identify new drugs for serious, underserved indications. Further development of BWC0977 will continue to receive support from the global non-profit partnership CARB-X. The latter is dedicated to accelerating research for new antibacterials to fight the dangerous global health issue caused by the ever-rising cases of antimicrobial resistance.
More information: https://www.prnewswire.com/in/news-releases/bugworks-research-inc-secures-us-18m-series-b1-funding-from-reputed-global-investor-syndicate-the-eu-uk-japan-south-africa-amp-india-led-by-lightrock-india-855647581.html